Thyroid Cancer
Conditions
Brief summary
The management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected. The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT may allow better identification of recurrent disease, thus allowing for more patients to be treated with I-131 as a curative attempt.
Detailed description
The management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected. The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT may allow better identification of recurrent disease, thus allowing for more patients to be treated with I-131 as a curative attempt. Conducting this study we hope to find whether I-124 PET/CT allows for detection of more lesions in patients with suspected recurrent thyroid cancer than the current standard of care represented by I-123 WBS and F-18 FDG PET/CT.
Interventions
Sponsors
Stanford University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
- Patient at Nuclear Medicine clinic at Stanford University Medical Center * Treated thyroid cancer. * Detectable levels of Tg. * Referred for I-123 WBS and F-18 FDG PET/CT for detection of recurrent thyroid cancer. * Able to have a I-124 PET/CT the day after I-123 WBS and F-18 FDG PET/CT * Patients older than 18-year-old. * Patients with history of treated thyroid cancer and suspected recurrent thyroid cancer based on detectable levels of Tg. * Patients must have I-123 WBS and F-18 FDG PET/CT performed prior to the I-124 PET/CT. * Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them.
Exclusion criteria
- Patients who are not eligible for I-123 WBS and F-18 FDG PET/CT. * Patients who cannot complete I-123 WBS and F-18 FDG PET/CT. * Pregnant women. * Healthy volunteers. * Patients participating in other research studies.
Outcome results
None listed